In fact, some experimental evidence suggests that EXOs might enhance tumor cell resistance to anticancer agents, as they might up-regulate the expression of factors, for example, ion channels such as CLIC1, which are related to the reduced activity of anticancer agents such as VIN. Here, CLIC1 is linked to neoplasm.